Typicality: | 0.641 |
Saliency: | 0.608 |
in humans | 20 | other |
in this first cohort | 11 | temporal |
through clinical trials | 11 | other |
drug → be proven → safe | 103 |
drug → be shown to be → safe | 89 |
drug → be proven to be → safe | 56 |
drug → be proved → safe | 17 |
drug → be demonstrated to be → safe | 14 |
drug → be shown → safe | 5 |
drug → be proved to be → safe | 4 |
negative | neutral | positive |
0.150 | 0.463 | 0.387 |
Raw frequency | 288 |
Normalized frequency | 0.608 |
Modifier score | 0.904 |
Perplexity | 32.288 |